Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD)

M. Ripolone, R. Violano, D. Ronchi, S. Mondello, A. Nascimbeni, I. Colombo, G. Fagiolari, A. Bordoni, F. Fortunato, V. Lucchini, S. Simona, M. Filosto, O. Musumeci, P. Tonin, T. Mongini, S. Previtali, L. Morandi, C. Angelini, M. Mora, M. SandriM. Sciacco, A. Toscano, G. P. Comi, M. Moggio

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Aims: Pompe disease is an autosomal recessive lysosomal storage disorder resulting from deficiency of acid α-glucosidase (GAA) enzyme. Histopathological hallmarks in skeletal muscle tissue are fibre vacuolization and autophagy. Since 2006, enzyme replacement therapy (ERT) is the only approved treatment with human recombinant GAA alglucosidase alfa. We designed a study to examine ERT-related skeletal muscle changes in 18 modestly to moderately affected late onset Pompe disease (LOPD) patients along with the relationship between morphological/biochemical changes and clinical outcomes. Treatment duration was short-to-long term. Methods: We examined muscle biopsies from 18 LOPD patients at both histopathological and biochemical level. All patients underwent two muscle biopsies, before and after ERT administration respectively. The study is partially retrospective because the first biopsies were taken before the study was designed, whereas the second biopsy was always performed after at least 6 months of ERT administration. Results: After ERT, 15 out of 18 patients showed improved 6-min walking test (6MWT; P = 0.0007) and most of them achieved respiratory stabilization. Pretreatment muscle biopsies disclosed marked histopathological variability, ranging from an almost normal pattern to a severe vacuolar myopathy. After treatment, we detected morphological improvement in 15 patients and worsening in three patients. Post-ERT GAA enzymatic activity was mildly increased compared with pretreatment levels in all patients. Protein levels of the mature enzyme increased in 14 of the 18 patients (mean increase = +35%; P < 0.05). Additional studies demonstrated an improved autophagic flux after ERT in some patients. Conclusions: ERT positively modified skeletal muscle pathology as well as motor and respiratory outcomes in the majority of LOPD patients.

Original languageEnglish
Pages (from-to)449-462
JournalNeuropathology and Applied Neurobiology
Volume44
Issue number5
DOIs
Publication statusPublished - 2018

Fingerprint

Glycogen Storage Disease Type II
Enzyme Replacement Therapy
Skeletal Muscle
Muscles
Biopsy
Late Onset Disorders
Glucosidases
Skeletal Muscle Fibers
Autophagy
Enzymes
Walking
Therapeutics

Keywords

  • Acid alpha-glucosidase deficiency
  • Autophagy
  • Enzyme replacement therapy
  • Pompe disease

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Histology
  • Neurology
  • Clinical Neurology
  • Physiology (medical)

Cite this

Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD). / Ripolone, M.; Violano, R.; Ronchi, D.; Mondello, S.; Nascimbeni, A.; Colombo, I.; Fagiolari, G.; Bordoni, A.; Fortunato, F.; Lucchini, V.; Simona, S.; Filosto, M.; Musumeci, O.; Tonin, P.; Mongini, T.; Previtali, S.; Morandi, L.; Angelini, C.; Mora, M.; Sandri, M.; Sciacco, M.; Toscano, A.; Comi, G. P.; Moggio, M.

In: Neuropathology and Applied Neurobiology, Vol. 44, No. 5, 2018, p. 449-462.

Research output: Contribution to journalArticle

Ripolone, M, Violano, R, Ronchi, D, Mondello, S, Nascimbeni, A, Colombo, I, Fagiolari, G, Bordoni, A, Fortunato, F, Lucchini, V, Simona, S, Filosto, M, Musumeci, O, Tonin, P, Mongini, T, Previtali, S, Morandi, L, Angelini, C, Mora, M, Sandri, M, Sciacco, M, Toscano, A, Comi, GP & Moggio, M 2018, 'Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD)', Neuropathology and Applied Neurobiology, vol. 44, no. 5, pp. 449-462. https://doi.org/10.1111/nan.12414
Ripolone, M. ; Violano, R. ; Ronchi, D. ; Mondello, S. ; Nascimbeni, A. ; Colombo, I. ; Fagiolari, G. ; Bordoni, A. ; Fortunato, F. ; Lucchini, V. ; Simona, S. ; Filosto, M. ; Musumeci, O. ; Tonin, P. ; Mongini, T. ; Previtali, S. ; Morandi, L. ; Angelini, C. ; Mora, M. ; Sandri, M. ; Sciacco, M. ; Toscano, A. ; Comi, G. P. ; Moggio, M. / Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD). In: Neuropathology and Applied Neurobiology. 2018 ; Vol. 44, No. 5. pp. 449-462.
@article{d66c5d29e22349f2a3ae4676da5e4a66,
title = "Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD)",
abstract = "Aims: Pompe disease is an autosomal recessive lysosomal storage disorder resulting from deficiency of acid α-glucosidase (GAA) enzyme. Histopathological hallmarks in skeletal muscle tissue are fibre vacuolization and autophagy. Since 2006, enzyme replacement therapy (ERT) is the only approved treatment with human recombinant GAA alglucosidase alfa. We designed a study to examine ERT-related skeletal muscle changes in 18 modestly to moderately affected late onset Pompe disease (LOPD) patients along with the relationship between morphological/biochemical changes and clinical outcomes. Treatment duration was short-to-long term. Methods: We examined muscle biopsies from 18 LOPD patients at both histopathological and biochemical level. All patients underwent two muscle biopsies, before and after ERT administration respectively. The study is partially retrospective because the first biopsies were taken before the study was designed, whereas the second biopsy was always performed after at least 6 months of ERT administration. Results: After ERT, 15 out of 18 patients showed improved 6-min walking test (6MWT; P = 0.0007) and most of them achieved respiratory stabilization. Pretreatment muscle biopsies disclosed marked histopathological variability, ranging from an almost normal pattern to a severe vacuolar myopathy. After treatment, we detected morphological improvement in 15 patients and worsening in three patients. Post-ERT GAA enzymatic activity was mildly increased compared with pretreatment levels in all patients. Protein levels of the mature enzyme increased in 14 of the 18 patients (mean increase = +35{\%}; P < 0.05). Additional studies demonstrated an improved autophagic flux after ERT in some patients. Conclusions: ERT positively modified skeletal muscle pathology as well as motor and respiratory outcomes in the majority of LOPD patients.",
keywords = "Acid alpha-glucosidase deficiency, Autophagy, Enzyme replacement therapy, Pompe disease",
author = "M. Ripolone and R. Violano and D. Ronchi and S. Mondello and A. Nascimbeni and I. Colombo and G. Fagiolari and A. Bordoni and F. Fortunato and V. Lucchini and S. Simona and M. Filosto and O. Musumeci and P. Tonin and T. Mongini and S. Previtali and L. Morandi and C. Angelini and M. Mora and M. Sandri and M. Sciacco and A. Toscano and Comi, {G. P.} and M. Moggio",
year = "2018",
doi = "10.1111/nan.12414",
language = "English",
volume = "44",
pages = "449--462",
journal = "Neuropathology and Applied Neurobiology",
issn = "0305-1846",
publisher = "Wiley Blackwell",
number = "5",

}

TY - JOUR

T1 - Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD)

AU - Ripolone, M.

AU - Violano, R.

AU - Ronchi, D.

AU - Mondello, S.

AU - Nascimbeni, A.

AU - Colombo, I.

AU - Fagiolari, G.

AU - Bordoni, A.

AU - Fortunato, F.

AU - Lucchini, V.

AU - Simona, S.

AU - Filosto, M.

AU - Musumeci, O.

AU - Tonin, P.

AU - Mongini, T.

AU - Previtali, S.

AU - Morandi, L.

AU - Angelini, C.

AU - Mora, M.

AU - Sandri, M.

AU - Sciacco, M.

AU - Toscano, A.

AU - Comi, G. P.

AU - Moggio, M.

PY - 2018

Y1 - 2018

N2 - Aims: Pompe disease is an autosomal recessive lysosomal storage disorder resulting from deficiency of acid α-glucosidase (GAA) enzyme. Histopathological hallmarks in skeletal muscle tissue are fibre vacuolization and autophagy. Since 2006, enzyme replacement therapy (ERT) is the only approved treatment with human recombinant GAA alglucosidase alfa. We designed a study to examine ERT-related skeletal muscle changes in 18 modestly to moderately affected late onset Pompe disease (LOPD) patients along with the relationship between morphological/biochemical changes and clinical outcomes. Treatment duration was short-to-long term. Methods: We examined muscle biopsies from 18 LOPD patients at both histopathological and biochemical level. All patients underwent two muscle biopsies, before and after ERT administration respectively. The study is partially retrospective because the first biopsies were taken before the study was designed, whereas the second biopsy was always performed after at least 6 months of ERT administration. Results: After ERT, 15 out of 18 patients showed improved 6-min walking test (6MWT; P = 0.0007) and most of them achieved respiratory stabilization. Pretreatment muscle biopsies disclosed marked histopathological variability, ranging from an almost normal pattern to a severe vacuolar myopathy. After treatment, we detected morphological improvement in 15 patients and worsening in three patients. Post-ERT GAA enzymatic activity was mildly increased compared with pretreatment levels in all patients. Protein levels of the mature enzyme increased in 14 of the 18 patients (mean increase = +35%; P < 0.05). Additional studies demonstrated an improved autophagic flux after ERT in some patients. Conclusions: ERT positively modified skeletal muscle pathology as well as motor and respiratory outcomes in the majority of LOPD patients.

AB - Aims: Pompe disease is an autosomal recessive lysosomal storage disorder resulting from deficiency of acid α-glucosidase (GAA) enzyme. Histopathological hallmarks in skeletal muscle tissue are fibre vacuolization and autophagy. Since 2006, enzyme replacement therapy (ERT) is the only approved treatment with human recombinant GAA alglucosidase alfa. We designed a study to examine ERT-related skeletal muscle changes in 18 modestly to moderately affected late onset Pompe disease (LOPD) patients along with the relationship between morphological/biochemical changes and clinical outcomes. Treatment duration was short-to-long term. Methods: We examined muscle biopsies from 18 LOPD patients at both histopathological and biochemical level. All patients underwent two muscle biopsies, before and after ERT administration respectively. The study is partially retrospective because the first biopsies were taken before the study was designed, whereas the second biopsy was always performed after at least 6 months of ERT administration. Results: After ERT, 15 out of 18 patients showed improved 6-min walking test (6MWT; P = 0.0007) and most of them achieved respiratory stabilization. Pretreatment muscle biopsies disclosed marked histopathological variability, ranging from an almost normal pattern to a severe vacuolar myopathy. After treatment, we detected morphological improvement in 15 patients and worsening in three patients. Post-ERT GAA enzymatic activity was mildly increased compared with pretreatment levels in all patients. Protein levels of the mature enzyme increased in 14 of the 18 patients (mean increase = +35%; P < 0.05). Additional studies demonstrated an improved autophagic flux after ERT in some patients. Conclusions: ERT positively modified skeletal muscle pathology as well as motor and respiratory outcomes in the majority of LOPD patients.

KW - Acid alpha-glucosidase deficiency

KW - Autophagy

KW - Enzyme replacement therapy

KW - Pompe disease

UR - http://www.scopus.com/inward/record.url?scp=85021708376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021708376&partnerID=8YFLogxK

U2 - 10.1111/nan.12414

DO - 10.1111/nan.12414

M3 - Article

AN - SCOPUS:85021708376

VL - 44

SP - 449

EP - 462

JO - Neuropathology and Applied Neurobiology

JF - Neuropathology and Applied Neurobiology

SN - 0305-1846

IS - 5

ER -